In 2017, Ramaswamy and co-workers successfully delivered mRNA through LNP in order to treat a Factor IX (FIX)-deficient mouse as a model of hemophilia B. This study showed that repeated administration of the mRNA-LNPs complex did not cause innate immune responses in hemophilic mice [78]. This evidence concerns the gene F9 and hemophilia B.